RIBAJUSTE Clinical Trial Investigating the Efficacy and Safety of Dose Adaptation of Ribavirin

Inclusion Criteria: * 65 years \>Age \>= 18 years * Chronic hepatitis C documented by PCR performed within 3 months and at liver biopsy within 18 months or with serum markers of fibrosis performed within 3 months before inclusion or FibroScan performed * Naive patients for who the physician decided to initiate a combination treatment of chronic hepatitis C with pegylated interferon alfa-2a plus ribavirine * Genotype VHC-1 * Compensated liver disease (Child-Pugh \<=6) * Negative HBsAg test and HIV-RNA test * Negative pregnancy test at baseline in women in age of procreation and efficient contraception all along the treatment period, and up to 7 months after discontinuation for women and men * Signed consent form * Patient with a social cover Exclusion Criteria: * Non HCV liver disease * Non-1 HCV genotype * Organ transplant whatever the organ * Clinical or radiological evidence of liver carcinoma * Severe psychiatric disorder * Non compensated thyroid dysfunction * Woman pregnant or breast-feeding * Recent history of epilepsy (less than 6 months) * Absolute contraindications to one of the drug of combination therapy * Biological abnormalities at pre-treatment check-up, such as: Neutropenia (\<1500/mm³); Haemoglobinemia (\<13 g/dL for men et \<12 g/dL for women); Thrombopenia (\<90 000/mm³); * Kidney failure (creatinine clearance\>70 ml/min) * Hypersensitivity to epoetin or one of its excipients * Treatment by epoetin within 2 months prior inclusion * Chronic cardiac failure (grade III or IV - NYHA classification) * High blood pressure unwell-controlled (SBP \> 180 mmHg during inclusion in spite of hypertension treatment) * Previous history or risk of venous thrombosis * Major surgery within the previous 3 months